Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients

Background. Fibroblast growth factor-23 (FGF-23) is a phosphorus-regulating substance. Circulating FGF-23 levels increase markedly in dialysis patients and are independently associated with increased risk of mortality. Given the fact that cardiovascular disease is the leading cause of death in dialysis patients, the aim of this study was to test if elevated FGF-23 levels might be associated with left ventricular mass index (LVMI) and left ventricular index of myocardial performance (MPI) in maintenance haemodialysis patients. Methods. In this cross-sectional study, plasma FGF-23 concentrations were measured using a C-terminal human enzyme-linked immunosorbent assay kit, and echocardiography was performed in 128 maintenance haemodialysis patients (65 women and 63 men, mean age: 55.5 +/- 13 years, mean haemodialysis vintage: 52 +/- 10 months, all patients are on haemodialysis thrice a week) and 40 control subjects (21 women and 19 men; mean age: 54 +/- 11 years) with normal kidney function (eGFR > 90 mL/min/1.73 m(2)). Results. Serum FGF-23 levels were elevated when compared with age-and gender-matched controls with preserved kidney function [(median 958 RU/mL; interquartile range 106-1894 RU/mL) vs (median 27 RU/mL; interquartile range 11-35), P < 0.0001]. Patients with a history of coronary artery disease and aortic valve calcifications had higher levels of log FGF-23 than those without (3.00 +/- 0.22 vs 2.82 +/- 0.26, P = 0.002; and 3.06 +/- 0.19 vs 2.83 +/- 0.26, P = 0.0001, respectively). Patients with MPI > 0.47 had higher serum FGF-23 levels than those with MPI < 0.47 [(median 1156 RU/mL; interquartile range 396-1894 RU/mL) vs (median 657 RU/mL; interquartile range 106-1102 RU/mL), P = 0.0001]. Significant correlations were recorded between log FGF-23 levels and LVMI (r = 0.281, P = 0,007) and MPI (r = 0.555, P = 0.0001). Multivariable-adjusted regression analyses revealed that increased log FGF-23 concentrations were independently associated with increased left ventricular mass index (30% increase per 1-SD increase in log FGF-23 concentration, P = 0.002) and increased MPI (28.5% increase per 1-SD increase in log FGF-23 concentration, P - 0.001). Conclusions. Plasma FGF-23 concentration is independently associated with LVMI and MPI in maintenance haemodialysis patients. Further prospective studies are needed to clarify whether increased serum FGF-23 level is a marker or a potential mechanism for left ventricular involvement in patients with end-stage renal disease.

Yazar Kirkpantur, Alper
Balci, Mustafa
Gurbuz, Oguz Alp
Afsar, Baris
Canbakan, Basol
Akdemir, Ramazan
Ayli, Mehmet Deniz
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/3309
Tek Biçim Adres 10.1093/ndt/gfq539
Konu Başlıkları fibroblast growth factor-23
haemodialysis
left ventricular mass index
myocardial performance index
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı NEPHROLOGY DIALYSIS TRANSPLANTATION
Dergi Cilt Bilgisi 26
Dergi Sayısı 4
Sayfalar 1346 - 1354
Yayın Yılı 2011
Eser Adı
[dc.title]
Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients
Yazar
[dc.contributor.author]
Kirkpantur, Alper
Yazar
[dc.contributor.author]
Balci, Mustafa
Yazar
[dc.contributor.author]
Gurbuz, Oguz Alp
Yazar
[dc.contributor.author]
Afsar, Baris
Yazar
[dc.contributor.author]
Canbakan, Basol
Yazar
[dc.contributor.author]
Akdemir, Ramazan
Yazar
[dc.contributor.author]
Ayli, Mehmet Deniz
Yayın Yılı
[dc.date.issued]
2011
Yayıncı
[dc.publisher]
OXFORD UNIV PRESS
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Background. Fibroblast growth factor-23 (FGF-23) is a phosphorus-regulating substance. Circulating FGF-23 levels increase markedly in dialysis patients and are independently associated with increased risk of mortality. Given the fact that cardiovascular disease is the leading cause of death in dialysis patients, the aim of this study was to test if elevated FGF-23 levels might be associated with left ventricular mass index (LVMI) and left ventricular index of myocardial performance (MPI) in maintenance haemodialysis patients. Methods. In this cross-sectional study, plasma FGF-23 concentrations were measured using a C-terminal human enzyme-linked immunosorbent assay kit, and echocardiography was performed in 128 maintenance haemodialysis patients (65 women and 63 men, mean age: 55.5 +/- 13 years, mean haemodialysis vintage: 52 +/- 10 months, all patients are on haemodialysis thrice a week) and 40 control subjects (21 women and 19 men; mean age: 54 +/- 11 years) with normal kidney function (eGFR > 90 mL/min/1.73 m(2)). Results. Serum FGF-23 levels were elevated when compared with age-and gender-matched controls with preserved kidney function [(median 958 RU/mL; interquartile range 106-1894 RU/mL) vs (median 27 RU/mL; interquartile range 11-35), P < 0.0001]. Patients with a history of coronary artery disease and aortic valve calcifications had higher levels of log FGF-23 than those without (3.00 +/- 0.22 vs 2.82 +/- 0.26, P = 0.002; and 3.06 +/- 0.19 vs 2.83 +/- 0.26, P = 0.0001, respectively). Patients with MPI > 0.47 had higher serum FGF-23 levels than those with MPI < 0.47 [(median 1156 RU/mL; interquartile range 396-1894 RU/mL) vs (median 657 RU/mL; interquartile range 106-1102 RU/mL), P = 0.0001]. Significant correlations were recorded between log FGF-23 levels and LVMI (r = 0.281, P = 0,007) and MPI (r = 0.555, P = 0.0001). Multivariable-adjusted regression analyses revealed that increased log FGF-23 concentrations were independently associated with increased left ventricular mass index (30% increase per 1-SD increase in log FGF-23 concentration, P = 0.002) and increased MPI (28.5% increase per 1-SD increase in log FGF-23 concentration, P - 0.001). Conclusions. Plasma FGF-23 concentration is independently associated with LVMI and MPI in maintenance haemodialysis patients. Further prospective studies are needed to clarify whether increased serum FGF-23 level is a marker or a potential mechanism for left ventricular involvement in patients with end-stage renal disease.
Açıklama
[dc.description]
WOS: 000289309400034
Açıklama
[dc.description]
PubMed: 20813767
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
fibroblast growth factor-23
Konu Başlıkları
[dc.subject]
haemodialysis
Konu Başlıkları
[dc.subject]
left ventricular mass index
Konu Başlıkları
[dc.subject]
myocardial performance index
Haklar
[dc.rights]
info:eu-repo/semantics/openAccess
ISSN
[dc.identifier.issn]
0931-0509
ISSN
[dc.identifier.issn]
1460-2385
İlk Sayfa Sayısı
[dc.identifier.startpage]
1346
Son Sayfa Sayısı
[dc.identifier.endpage]
1354
Dergi Adı
[dc.relation.journal]
NEPHROLOGY DIALYSIS TRANSPLANTATION
Dergi Sayısı
[dc.identifier.issue]
4
Dergi Cilt Bilgisi
[dc.identifier.volume]
26
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1093/ndt/gfq539
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/3309
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
251
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
17 Temmuz 2024 23:40
Google Kontrol
Tıklayınız
FGF-23 patients levels haemodialysis increased increase associated interquartile ventricular concentration disease RU/mL) maintenance independently function kidney concentrations dialysis Patients [(median (median higher elevated artery history coronary calcifications without aortic Background respectively) Plasma Further prospective studies
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms